918²«ÌìÌÃ

½Ó´ý»á¼û918²«ÌìÌùٷ½ÍøÕ¾£¡

ÎÄÏ××ÊÁÏ

ÁªÏµ918²«ÌìÌÃ

918²«ÌìÌÃ

µç»°£º0570£­8788056

´«Õ棺0570£­8788381

ÓÊÏ䣺zjgykp@163.com

µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø

¶«¸Û4·2ºÅ

ÄúËùÔÚµÄÄ¿½ñλÖãºÊ×Ò³ > ÎÄÏ××ÊÁÏ > Ö×ÁöÀàÎÄÏ×
  • ¹û½ºµÄ¿¹Ö×Áö»îÐÔÑо¿½øÕ¹
  • Ðû²¼Ê±¼ä£º 2019/5/14¡¡µã»÷´ÎÊý£º4358¡¡
  •   
    ¹û½ºµÄ¿¹Ö×Áö»îÐÔÑо¿½øÕ¹
     
    ÀîÓ¢»ª 1 £¬Öì Íþ 1£¬2£ª£ª
    £¨1. ¸´µ©´óѧÉϺ£ÊеÚÎåÈËÃñÒ½Ôº ÉϺ£ 200240£»Õã½­´óѧ¹¤Òµ¼¼ÊõÑо¿Ôº º¼ÖÝ 310029£©
     
    Õª Òª£º±¾ÎÄͨ¹ý²éÔĽüÄêÀ´¹û½º¿¹Ö×Áö»îÐÔÑо¿µÄÏà¹ØÎÄÏ×£¬¶Ô½üÄêÀ´¹û½º¸ÄÉÆÖ×ÁöЧ¹ûÒÔ¼°¹û½º
    ºÍ²¿·Ö¿¹Ö×ÁöÒ©ÎïÖ®¼äµÄÏ໥×÷ÓýøÐÐ×ܽᣬ²¢ÆÊÎö¹û½ºÓëÌåÄÚ°ëÈéÌÇÄý¼¯ËØ-3 ÔÚ¿¹Ö×ÁöÖеÄ×÷Ó㬶Ô
    ¹û½º¿¹Ö×Áö»úÖƽøÐÐ̽ÌÖ ¡£Í¬Ê±Ö¸³ö¹û½º¿¹Ö×ÁöÑо¿µÄÉú³¤Ç÷ÊÆ£¬Îª¹û½ºµÄ¿¹Ö×ÁöÑо¿Ìṩ²Î¿¼ÒÀ¾Ý ¡£
    Òªº¦´Ê£º¹û½º ¿¹Ö×Áö »îÐÔÑо¿ ×ÛÊö
    doi: 10.11842/wst.2014.02.042 ÖÐͼ·ÖÀàºÅ£ºR285.5 ÎÄÏ×±êʶÂ룺A
     
    ¹û½ºÀ´Ô´ÓÚÖ²Îï½çµÄÒ»ÖÖ¸»º¬°ëÈéÌÇÈ©ËáµÄ ËáÐÔÔÓ¶àÌÇ£¬ÎªÖ²Îïϸ°û±ÚµÄ½á¹¹Éí·Ö£¬±» FAO/WHO ʳƷÌí¼Ó¼ÁÁªºÏίԱ»áÍƼöΪʳƷÌí¼Ó¼Á[1] ¡£ÓÉÓÚ ¹û½º¾ßÓÐ׿ԽµÄÄý½ºÐÔºÍÈ黯Îȶ¨ÐÔ¶øʹÆä³ÉΪ ʳƷ¹¤ÒµÖÐÒ»ÖÖÖØÒªµÄÌí¼Ó¼Á£¬ÔÚʳƷ¹¤ÒµÖпÉÓà ×÷Ôö³í¼Á¡¢½ºÄý¼ÁµÈ ¡£ÔÚÖÆÒ©¹¤ÒµÖпɵ¥¶À»òÓëÆäËû¸³ÐμÁÊÊÓÃÅäÖÆÈí¸à¡¢Ä¤¼Á¡¢Ë¨¼Á¡¢Î¢ÄÒµÈÒ©ÎïÖƼÁ[2] ¡£Ò©ÀíѧÑо¿±êÃ÷¹û½º×÷Ϊ¿ÉÈÜÐÔÉÅʳÏËά¾ßÓп¹¸¹Ðº¡¢¿¹°©¡¢ÖÎÁÆÌÇÄò²¡µÈ¹¦Ð§[3~5]£¬Ô½À´Ô½¶àµÄѧÕß½«Ä¿±êתÏòÑо¿¹û½ºµÄ¿¹Ö×ÁöЧ¹û£¬·¢Ã÷µÍ·Ö×Ó¹û½º¿É×÷ΪÌåÄÚ°ëÈéÌÇÄý¼¯ËØ-3£¨Galectin-3£©ÅäÌåµÄ¾ºÕùÐÔÒÖÖƼÁ£¬×èÖ¹Ö×ÁöµÄÐγÉÓëÉú³¤[6~8] ¡£Í¨¹ý´ó×Ú²éÔĺ£ÄÚÍâÎÄÏ׺ÍרÀû²éÔĵĻù´¡ÉÏ£¬±ÊÕ߶Թû½º¿¹Ö×ÁöµÄÑо¿¸Å¿ö½øÐÐ×ÛÊö ¡£
     
    1 ÎÄÏ×ÓëרÀûµÄÂþÑÜÇé¿ö
    ͨ¹ý¶Ô Google¡¢Sciencedirect¡¢Î¬ÆÕÊý¾Ý¿â¡¢Öйú ÖªÍøÊý¾Ý¿â¼°Öйú֪ʶ²úȨ¾ÖµÈ³£ÓÃרҵÊý¾Ý¿â¼°ÍøÕ¾½øÐйû½ºÓ뿹Ö×ÁöÒªº¦´ÊµÄËÑË÷ ¡£ÔÚάÆÕÓëÖйúÖªÍøÉÏËÑË÷µ½¹ØÓÚ¹û½º¿¹Ö×ÁöµÄÏà¹ØÎÄÏ×13ƪ£¬ÆäÖÐ 3 ƪÆÚ¿¯ÂÛÎÄ£¬10 ƪѧλÂÛÎÄ ¡£Öйú֪ʶ²ú È¨¾ÖËѵ½µÄ¹ØÓÚ¿¹Ö×Áö¹û½ºÏà¹ØרÀû 5 Ïî ¡£º£ÄÚ¹ØÓÚ¹û½º¿¹Ö×ÁöµÄÑо¿¿ÎÌâ×éÖ÷Òª¼¯ÖÐÓÚ¹ãÖÝҽѧԺ¡¢¶«±±Ê¦·¶´óѧ¡¢Ìì½ò´óѧ¡¢Î÷±±´óѧ¡¢µÚËľüÒ½´óѧ¡¢Õã½­´óѧ¼°Õã½­Ê¡Å©¿ÆÔºµÈ[9~11] ¡£ÎÒ¹ú¹ØÓÚ¹û½º¿¹Ö×ÁöµÄÑо¿Ê¼ÓÚ 2005 Ä꣬Ö÷Òª¼¯ÖÐÓÚ¸ÌéٵͷÖ×Ó ¹û½ººÍÈ˲Π¹û½º¶ÔÖ× ÁöµÄ×÷Ó÷½ Ãæ ¡£ÔÚ Sci£­encedirect ÉÏËѵ½¹ØÓÚ¹û½º¿¹Ö×ÁöÏà¹ØÂÛÎÄ 103 ƪ£¬Google ÉÏËѵ½Ïà¹ØÂÛÎÄ¡¢×¨ÀûÒÔ¼°ÊéÄ¿¹² 16 500 ÓàÌõ ¡£ÍâÑó¹ØÓÚ¿¹Ö×ÁöµÄÑо¿¿ÎÌâ×éÖ÷Òª¼¯ÖÐÓÚÃÀ¹úºÍÈÕ±¾£¬ÃÀ¹úÓÚ 1993 Äê¾ÍÓйØÓڵͷÖ×Ó¹û½º¿¹Ö×ÁöµÄרÀû£¬½ü 20 ÄêÀ´ÍâÑó¹ØÓÚ¹û½º¿¹Ö×ÁöµÄÑо¿È¡µÃÁË·ÉËÙ½ø²½£¬ÒÑÓдóÐÍÖÆÒ©ÆóÒµ½«¹û½ºÓ¦ÓÃÓÚÖƱ¸°ÐÏò¿¹Ö×ÁöÒ©Îï·½Ã棬ÆäÖйû½º°¢Ã¹ËØÒѽøÈëÁÙ´²Ç°½×¶Î[12~15] ¡£
     
    2 ¹û½ºÀ´Ô´
    ¹û½ºÎïÖÊÒÔÔ­¹û½º¡¢¹û½º¡¢¹û½ºËáµÄÐÎ̬¹ã²¼ ÓÚÖ²Îï½ç£¬¸ßµÈÖ²ÎïÓëµÍµÈÖ²ÎïÖнԺ¬ÓУ¬Ö÷Òª±£´æÓÚÏàÁÚϸ°û±ÚµÄÖмä²ã£¬Æð×ÅÁ¬½Óϸ°ûºÍÌìÈ»ÆÁÕϵÄ×÷Óà ¡£Ïà±È֮ϣ¬ÔÚ¸ù¡¢¾¥¡¢Ò¶¡¢¹ûʵµÈÆ÷¹ÙÖУ¬ÒÔ¹ûʵÖйû½ºµÄº¬Á¿×î¸ß£¬Èçɽ髡¢Æ»¹û¡¢¸Ì½ÛµÈ¹ûʵÖк¬Á¿ÆÄ·á[2]±ðµÄ£¬ºúÂܲ·µÄÈâÖʸù¡¢ÏòÈÕ¿ûµÄ »¨ÅÌ¡¢Ã¢¹ûÔü¡¢Ìð²Ë·ÏÆÉ¡¢²Ïɳ¡¢Î÷¹ÏƤ¡¢¸ÊÊí¡¢É³¼¬µÈÖÐÒ²º¬Óи»ºñµÄ¹û½º ¡£²î±ðÖ²ÎïÖеĹû½ºº¬Á¿¼û±í 1 ¡£
    918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü 
    Ä¿Ç°£¬ÕæÕý¾ßÓй¤ÒµÉú²ú¼ÛÖµµÄ¹û½ºÀ´Ô´ÓÚ¸Ì ½ÛÀࣨ°üÀ¨ÆÏÌÑèÖ¡¢³È¡¢Â«¸Ì¡¢ºúèÖ¡¢ÄûÃÊ¡¢¸Ì½ÛµÈ£©¹ûƤ¡¢Æ»¹ûÕ¥Ö­·ÏÔü¡¢ÌÇÓÃÌð²ËÔü¡¢¶¹¸¯²ñºÍ²ÏɳµÈ£¬ÆäÖÐ×îÓÐÌáÈ¡¼ÛÖµµÄÊ×ÍƸ̽ÛÀà¹ûƤ ¡£Ìð²ËÔü¹û½ºÔÚµÚ¶þ´ÎÊÀ½ç´óսʱÒÑÓÐÉú²ú£¬µ«ÓÉÓÚ±£´æ×Å´ó×Ú µÄÖÐÐÔÌDzàÁ´£¬·Ö×ÓÁ¿Ïà¶Ô½ÏµÍ£¬¸»ÒÒËáõ¥»¯£¬ÔÚʳƷÌí¼Ó¼ÁÓ¦ÓÃÖб»ÈÏΪÄÚÔÚÖÊÁ¿½Ï²î ¡£
      
    3 ¹û½ºµÄ·ÖÀà
    ÖÖÖÖ¹û½ºÎïÖÊÖ®¼äµÄÖØÒª²î±ðÊÇËüÃǵÄÈܽâÐÔÄÜ¡¢·Ö×ӽṹ¡¢¼×õ¥º¬Á¿ºÍõ¥»¯Ë®Æ½£¬Æä´ú±íÐԽṹ¼ûͼ 1 ¡£Òò´Ë¹û½ºÆ¾¾ÝÈܽâÐÔÄÜ¿É·ÖΪˮÈÜÐÔ¹û½ººÍË®²»ÈÜÐÔ¹û½º£»°´·Ö×ÓÁ¿µÄ¾Þϸ·ÖΪµÍ·Ö×Ó¹û½ººÍ¸ß·Ö×Ó¹û½º£»°´ÌáÈ¡ºóÊÇ·ñ¾­¹ý½á¹¹¸ïзÖΪÌáÈ¡¹û½ººÍ¸ÄÐÔ¹û½º ¡£Ò»°ãÉÌÒµ¹û½ºÆ¾¾Ýõ¥»¯Ë®Æ½£¬·ÖΪµÍõ¥¹û½ººÍ¸ßõ¥¹û½º£¬µÍõ¥¹û½º»¹°üÀ¨õ£°·»¯¹û½ººÍ¸ÄÐÔ¹û½º ¡£¹û½ºµÄõ¥»¯¶ÈÊÇÖ¸¼×õ¥»¯µÄ°ëÈéÌÇÈ©Ëá»ùÕ¼×Ü°ëÈéÌÇÈ©Ëá»ùµÄ°Ù·Ö±È£¬¼´¹û½ºÖÐƽ¾ùÿ 100 ¸ö°ëÈéÌÇÈ©Ëá»ùλ C6 ÉÏÒÔ¼×õ¥»¯ÐÎʽ±£´æµÄ¸öÊý£¬½ÐDE Öµ»ò DM Öµ ¡£
    3.1 ¸ß¼×Ñõ»ù¹û½º
    ¸ß ¼× Ñõ »ù ¹û ½º£¨High Methoxyl Pectins or High Ester Pectins£¬HMP£©¼´ ¸ß õ¥ ¹û ½º £¬Æä °ë Èé ÌÇ µ¥ Ôª ͨ ³£ÓÐÁè¼Ý 50%µÄ±»õ¥»¯£¬¼´ DE Öµ£¾50%£¬Æä DM ÖµÔÚ 7.0% ~ 16.3%Ö®¼ä ¡£¸ß õ¥¹û ½º ²» Óë Ca2 +±¬·¢·´Ó¦£¬Æä Äý½º»ú ÖÆ ÊÇ ÓÉ ÓÚ ¹û ½º ·Ö ×Ó ¼ä Êè Ë® ¼ü ÒÔ ¼°Çâ¼üµÄÏ໥ ×÷ Óà £¬ ÐÎ ³É Äý ½º ÒÀ Àµ ÓÚ Ëá µÄ º¬ Á¿¡¢¹û ½ºµÄÖÖÀࡢŨ¶ÈºÍ¿ÉÈÜÐԹ̺¬ÎïµÄº¬Á¿ ¡£
    3.2 µÍ¼×Ñõ»ù¹û½º
    µÍ ¼× Ñõ »ù ¹û ½º £¨Low Methoxyl Pectins or Low Easter Pectins£¬LMP£© ±» õ¥ »¯ µÄ °ë Èé ÌÇ µ¥ Ôª ²» ³¬ ¹ý 50%£¬¼´ DE Öµ£¼50%£¬DM Öµ£¼7.0% ¡£µÍ¼×Ñõ»ù¹û½º¿ÉÓë Ca2+ ÐγÉÄý½º ¡£LMP Äý½º»úÖÆÔòÊÇÓÉÓÚ¹û½º·Ö×ÓÉÏÓÎÀëËó»ù½Ï¶à£¬ÄܺͶþ¼Û»ò¶à¼Û½ðÊôÑôÀë×ÓÐγɽ»Áª½á¹¹£¬Í¬Ê±Æðµ½Öк͹û½ºÄÚÓ°Ïì·Ö×Ó¼ä½áºÏµÄÒõÀë×ÓµÄ×÷Óà ¡£ËüÐγÉÄý½ºµÄÇ¿¶ÈÈ¡¾öÓÚ¹û½ºÅ¨¶È¡¢ÖÖÀà¡¢¿ÉÈÜÐÔ¹ÌÐÎÎﺬÁ¿¡¢pH ¹æÄ£¡¢»º³åҺŨ¶ÈºÍCa2+ µÄº¬Á¿ ¡£µÍõ¥¹û½º¶Ô¶þ¼Û½ðÊôÀë×ÓµÄòüºÏÌØÐÔ±»Ó¦ÓÃÔÚÒ½Ò©ÅųýÖؽðÊô·½Ãæ ¡£
    3.3 õ£°·»¯¹û½º
    µ±¹û½ºÔÚÍÑõ¥Àú³ÌÖÐÒÔ°±È¡´úËᣬõ¥»¯µÄ»ùÍÅÔò»á±»õ£°·»ùËùÈ¡´ú£¬ÐγÉõ£°·¹û½º ¡£õ£°·»¯¶È£¨Degree of Amid -action£¬DA£©ÊÇÖ¸ôÈ»ù»ùÍÅ´¦ÓÚõ£°·ÐÎʽµÄ°Ù·ÖÊý ¡£´ó¶¼ÉÌÆ·µÍõ¥¹û½º¶¼ÊÇõ£°·»¯£¬µä·¶µÄ DA ÖµÔÚ 15%~22%¼ä ¡£õ£°·»¯¹û½ºÄÜÔÚ½Ï ¸ßζÈÏÂÄý½º»¯£¬ÏÕЩ²»ÐèÒªCa2 +£¬Òò´ËµÍ¼×Ñõ»ùõ£°·¹û½ºµÄÄý½ºÌØÐÔÀàÊÜ Ca2 +Ũ¶ÈÓ°Ïì¸üС ¡£
    3.4 ¸ÄÐÔ¹û½º
    ¸Ä ÐÔ ¹û ½º £¨Modified Pectin£¬MP£© ÊÇ Í¨ ¹ý µ÷ Õû pH£¬ÀûÓÃËá¡¢¼îºÍøµÈ¼¼ÊõË®½âÌìÈ»¹û½º¶ø»ñµÃµÄ Ò»ÖÖ·Ö×ÓÁ¿¸üС¡¢õ¥»¯¶È¸üµÍ¡¢ÎÞ·ÖÖ§µÄ¹û½º¶àÌÇ£¬·Ö×ÓÁ¿½µµÍÖÁ 20 000 ÒÔÏ ¡£ÓëÌìÈ»¹û½ºÏà±È£¬MP µ¥ÌÇ×é·ÖûÓлù´¡µÄ±ä¸ï£¬¸ü¸»º¬°ëÈéÌÇÈ©Ëá¡¢ÊóÀîÌǺÍľÌÇ£»²¢ÇÒ¾ßÓбÈÌìÈ»¹û½º¸ü¶àµÄÉúÀí¹¦Ð§£¬Æä·Ö×ÓÁ¿½µµÍҲʹ¸ÄÐÔ¹û½º¸üÈÝÒ×±»»úÌåÎüÊÕ¶ø½øÈëѪҺѭ»· ¡£Ä¿Ç°Êг¡ÉÏ·ºÆðµÄ¹û½º¾ùΪ¸ÄÐԸ̽۹û½º£¨Modified Citrus Pectin£¬MCP£© ¡£¾ÝÑо¿ÈËÔ± ·¢Ã÷£º¸ÄÐԸ̽۹û½º¾ßÓнÏÇ¿µÄÕ³¸½¹¦Ð§£¬ËüÌØÒìµØɱÉËÒÑÍ»±äϸ°û£¬Ê¹Í»±äϸ°ûÔÚδÐγÉ֮ǰ¼´±»Çå³ý£»Í¬Ê±×èֹͻ±äϸ°û¼äµÄ¾Û¼¯¼°Í»±äϸ°ûÕ³¸½µ½ÁÚ½üµÄϸ°ûºÍ×éÖ¯£¬Òò´Ë¾ßÓÐÁ¼ºÃµÄ¿¹Ö×ÁöÐÔÄÜ[7] ¡£
    ͼ 1 ¹û½ºµÄ´ú±íÐԽṹ
    918²©ÌìÌÃ(ÖйúÇø)Æì½¢Ìü
     
    4 º£ÄÚÍâÑо¿ÏÖ×´
    ¹û½ºÒÖÖÆÖ×ÁöµÄÑо¿Ö÷Òª°üÀ¨²î±ðÀ´Ô´µÄ¹û ½º¶Ô²î±ðÖ×ÁöµÄ¿¹Ö×ÁöЧ¹û¼°¸ÄÐԸ̽۹û½º¿¹Ö×Áö»úÀí ¡£
    4.1 Ô­ÁÏÀ´Ô´
    Ä¿Ç°ÕæÕýÓй¤ÒµÉú²ú¼ÛÖµµÄ¹û½ºÀ´Ô´Îª¸ÌéÙ¹ûƤºÍÆ»¹ûÕ¥Ö­·ÏÔü ¡£Òò´Ë¹ØÓÚ¿¹Ö×Áö¹û½ºµÄÀ´Ô´Ö÷Òª¼¯ÖÐÓÚÆ»¹û¹û½ººÍ¸Ì½Û¹û½ºµÄÑо¿£¬ÌرðÊǹØÓڵͷÖ×Ӹ̽۹û½º¿¹Ö×Áö»îÐÔµÄÑо¿Öڶ࣬ռ¹û½º¿¹Ö×ÁöÏà¹ØÑо¿µÄ 97%ÒÔÉÏ ¡£µ«Ò²Óв¿·Ö¿ÆÑÐÊÂÇéÕ߶ÔÈ˲ιû½º¡¢Ìð²Ë¹û½º¡¢Î÷ºìÊÁ¹û½º¡¢ÄϹϹû½º¡¢Â̲è¹û½ºµÄ¿¹Ö×Áö»îÐԵȽøÐÐÁËʵÑéÐÔÑо¿[16~18] ¡£
    ·¶ÓñÓ¨[10]½øÐÐÁËÈ˲ιû½º¶Ôϸ°ûǨÒƵÄÓ°Ï켫µÄÑо¿£¬½á¹û·¢Ã÷È˲ιû½ºÄÜÌØÒìÐÔÒÖÖÆ L-929 ϸ°ûµÄǨÒÆ£¬Óë±ÈÕÕ×éϸ°ûÏà±È£¬È˲ιû½º¶Ôϸ°ûǨÒÆËٶȵÄ****ÒÖÖÆ¿É´ï 60£¥ ¡£ÆäÒÖÖÆ×÷Óò»ÊÜѪÇåµÄÓ°Ï죬˵Ã÷È˲ιû½ºÊÇѪÇåÒÀÀµºÍѪÇå·ÇÒÀÀµÁ½ÖÖǨÒÆ;¾¶µÄÒÖÖƼÁ£¬²¢ÇÒ·¢Ã÷¸»º¬¾Û°ëÈéÌÇÈ©ËᣨHG£©½á¹¹ÓòµÄ¹û½º¼¶·Ö¶Ôϸ°ûǨÒÆËٶȾßÓÐÃ÷ÏÔµÄÒÖÖÆ×÷Óã¬Í¨¹ý̽ÌÖÁËÈ˲ιû½ºÔÚϸ°ûĤÉϵÄÊÜÌå·Ö×Ó£¬½á¹û·¢Ã÷È˲ΠRG-¢ñÐÍºÍ HG Ð͹û½º¶Ôϸ°ûǨÒƵÄÓ°Ïì²¢²»ÊÇÓÉ Galectin-3 ½éµ¼£¬ËµÃ÷È˲ιû½ººÍ¸ÌéÙ¹û½ºµÄ¿¹Ö×Áö»úÖƲ»ÍêÈ«ÏàËÆ ¡£ÐìºñΡ[11]¶ÔµÍ·Ö×Ó¸ÌéÙ¹û½ºÉ±É˽᳦°©Ï¸°ûÀú³ÌÖÐÒªº¦µòÍöÂѰ׵Ļ½øÐÐÁËÑо¿£¬·¢Ã÷µÍ·Ö×Ó¸ÌéÙ¹û½º²»µ«¶ÔÖ±³¦°©¸ÎתÒÆÔîµÄÐγÉÓÐÒÖÖÆ×÷Ó㬲¢ÇÒ¹ØÓÚÔ­·¢ÔîÒ²ÓÐÒ»¶¨µÄÏÞÖÆ×÷Ó㬶Խ᳦°©Ï¸°ûÖê SW116¡¢ HCT116¡¢HT -29¡¢SW620¡¢SW480 ¾ù ÓÐ ÒÖ ÖÆ ×÷ Óà £¬ÇÒ³ÊŨ¶ÈÒÀÀµÐÔ£¬ÆäÖÐ HCT116 ×îÃô¸Ð ¡£µÍ·Ö×Ó¸ÌéÙ¹û½º¿ÉÒÔÓÕµ¼½á³¦°©Ï¸°ûµòÍö£¬Æä·Ö×Ó»úÖÆ¿ÉÄÜÊǻÄÚÔ´ÐÔµòÍö;¾¶ÖÐÒªº¦ÂÑ°× Caspase-9£¬½ø¶ø¼¤»î Caspase-3 Áѽâ PARP ÓÕµ¼Ï¸°ûµòÍö ¡£ÕÅÎIJ©[9]·¢Ã÷¸ÄÐԸ̽۹û½º¶Ô¹¬¾±°©ºÍ¸Î°©ÓÐÒ»¶¨µÄÒÖÖÆ»îÐÔ£¬ÇÒ¸ÄÐÔ¹û½ºµÄ¼×Ñõ»ùº¬Á¿¶ÔÆ俹°©»îÐÔÓÐÒ»¶¨Ó°Ïì ¡£
    Tazawa K µÈ[16]Ñо¿ÁËÆ»¹û¹û½º¶ÔÖ±³¦°©µÄÒÖÖÆ»îÐÔ£¬·¢Ã÷ÆäÄÜͨ¹ýÔöǿʵÑéСÊóµÄÃâÒß¹¦Ð§£¬½µµÍÑ×Ö¢´Ì¼¤´Ó¶øÓÐЧ×èÖ¹Ö±³¦°©µÄ±¬·¢ ¡£Guess B W µÈ[13]·¢Ã÷¸ÌéÙ¸ÄÐÔ¹û½ºÄܹ»ÒÖÖÆÇ°ÁÐÏÙ°©£¬¸ÄÉÆÇ°ÁÐÏÙ°©»¼ÕßµÄÉú»îÖÊÁ¿Tin W W µÈ[14]±¨µÀ¹û½º¾ßÓÐÒÖÖƷΰ©µÄЧ¹û£¬Äܹ»ÓÐЧ±ÜÃâ·Î°©¶ñ»¯£¬²¢ÇÒÈÏΪ°ëÈéÌÇÈ©Ëá¹ØÓÚÆ俹°©ÓÐ×ÅÖØÒªµÄÓ°Ïì ¡£
    4.2 ¸ÄÐԸ̽۹û½ºµÄ¿¹Ö×Áö»úÀí
    Ä¿Ç°¹ØÓÚÒÖÖÆÖ×ÁöµÄÖÖÀàÑо¿Ö÷Òª¼¯ÖÐÓڽ᳦°©¡¢ÈéÏÙ°©¡¢¹¬¾±°©¡¢Ç°ÁÐÏÙ°©¼°·Î°©µÈ£¬¶ø¹ØÓÚ¿¹Ö×Áö»úÀíµÄÑо¿Ö÷Òª¼¯ÖÐÓڸ̽۹û½ºÑо¿ ¡£´ó¶¼¿ÆÑÐÊÂÇéÕßÈÏΪ¸ÄÐԸ̽۹û½ºµÄ¿¹Ö×Áö×÷ÓûúÖÆ ÓëÖ×ÁöÏà¹ØÂÑ°× Galectin-3 ÓйØ
    [17~19] ¡£Galectin-3 ÊÇÒ»Öֶ๦ЧÂÑ°×£¬¹ã·ºÂþÑÜÓÚÕý³£Ï¸°û¼°Ö×Áöϸ°û£¬¼ÓÈëµ÷Àíϸ°ûÉú³¤ÓëÆÊÎö£¬ÓëÖ×ÁöµÄÐγɡ¢Éú³¤ ÓëתÒƵÄÈ«Àú³ÌÃÜÇÐÏà¹Ø£¬Æ书Ч±í´ïÉæ¼°Ö×ÁöµÄÇÖÏ®ÓëÕ³¸½¡¢Ö×ÁöÐÂÉúѪ¹ÜµÄÐγɡ¢Ï¸°ûµÄµòÍöµ÷
    ¿Ø¼°ÃâÒßʶ±ðµÈ·½Ãæ[20~22] ¡£µÍ·Ö×Ó¸ÄÐԸ̽۹û½º¿ÉÒÔ×÷ΪÌåÄÚ Galectin-3 µÄÅäÌåµÄ¾ºÕùÐÔÒÖÖƼÁ£¬¹Ø±ÕÖ×Áöϸ°ûÍâòµÄ Galectin-3 λµã£¬×èÖ¹Ö×Áöϸ°ûµÄÐγÉÓëÉú³¤[23£¬24] ¡£¹ØÓڵͷÖ×Ӹ̽۹û½ºÒÖÖÆÖ×ÁöÖ÷Ҫͨ¹ýÒÔϼ¸¸ö»·½Ú ¡£
    4.2.1 ¿ØÖÆÖ×Áöϸ°ûµÄʧ³²µòÍö£¬ÓÕµ¼Ï¸°ûµòÍöÑо¿ÏÔʾ£¬µÍ·Ö×Ó¸ÄÐԸ̽۹û½º£¨LCP£©Ó°ÏìÈËÇ°ÁÐÏÙ°©Ï¸°û JAC-1 µÄϸ°ûÖÜÆÚ£¬Ïµ÷Æä cyclin-B ¼° cdc2£¬Ê¹Ï¸°û»ýÀÛÓÚ G2/M ÆÚ£¬ÓÕµ¼±¬·¢µòÍö ¡£ MCP ¿ÉÃ÷ÏÔÒÖÖÆ Galectin -3 ¶Ôʧ³²µòÍö µÄ¶Ô¿¹×÷ÓÃ[25£¬26] ¡£Jackson C L µÈ[27]Ñо¿Ö¤Êµ MCP ×ÔÉíÓµÓÐÓÕµ¼µòÍöµÄÄÜÁ¦£¬²¢Äܹ»ÓÐЧ¶Ô¿¹ Galectin-3 µÄ¿¹µòÍö×÷Óà ¡£ÔÚ MCP ÓÕµ¼¶à·¢ÐÔ¹ÇËèÁöµòÍöµÄʵÑéÖУ¬ µòÍöÐźű»Ö¤Ã÷ÓÉ Caspase-8 ͨ±¨ÖÁ Caspase-3[28] ¡£
    4.2.2 ÒÖÖÆÖ×Áöϸ°ûÔÚתÒÆ°ÐÆ÷¹ÙµÄ×Å´²
    Ö×Áöϸ°ûÔÚʧ³²ºó£¬Í¨¹ýÑ­»·µÖ´ïÔ¶´¦°ÐÆ÷¹Ù£¬ÔÚÆäÂö¹ÜϵͳÖÐÍ£Áô£¬ÔÚ Galetin-3 µÄ×÷ÓÃÏ£¬×ªÒƵÄÖ×Áöϸ°ûÓëѪ¹ÜÄÚƤϸ°ûÕ³¸½×Å´² ¡£×Å´²ºó£¬Galectin-3 ÓëÖ×ÁöÏà¹ØT ¿¹Ô­Ï໥×÷Óã¬ÏÈÊÇ½é µ¼Ö×Áöϸ°û¶¨Î»ÓÚѪ¹ÜÄÚƤϸ°û£¬½ô½Ó×ÅÓÖ´ÙʹÖ×Áöϸ°ûÖ®¼äͬÐ;ۼ¯ÓÚ×Å´²µã[29] ¡£MCP ÓÐÇ¿´óµÄ¿¹Õ³¸½ÌØÐÔ£¬ÄÜÓÐЧ×ÌÈÅ°©Ï¸°ûÖ®¼äµÄͬÐ;ۼ¯¼°ÆäÓëѪ¹ÜÄÚƤϸ°ûÏàÕ³¸½ ¡£Lehr J E µÈ[30]ÔÚÌåÍâʵÑéÖÐ¶Ô 11 ÖÖ¿¹Õ³¸½Ð¡·Ö×Ó½øÐÐÁ˲âÊÔ£¬Ö¤Êµ MCP ×îÄܹ»×è¶ÏÇ°ÁÐÏÙ°©Ï¸°ûÓë¹ÇËèÄÚƤϸ°ûÏàÕ³¸½ ¡£ÌåÄÚÊÔÑéÖУ¬MCP ÒÖÖÆÈéÏÙ°©Ï¸°ûºÍÇ°ÁÐÏÙ°©Ï¸°ûÔڷΡ¢¹Ç×éÖ¯ÖÐÐγÉתÒÆÁöµÄÓÐЧÂÊ´óÓÚ 90% ¡£
    4.2.3 ÒÖÖÆÖ×Áöϸ°ûµÄÇÖÏ®
    Ö×Áöϸ°û×Å´²ÓÚ°ÐÆ÷¹Ùºó£¬ÔÚ΢Ѫ¹ÜÄÚÔöÖ³£¬½ø¶ø´©Í¸Ñª¹Ü±Ú£¬ÇÖÈëʵÖÊÐγÉתÒÆÁö ¡£ÔÚÕý³£Ï¸°ûÓëÖ×Áöϸ°ûÖ®¼ä£¬±£´æÓÉ»ùµ×ĤºÍϸ°ûÍâ»ùÖÊ×é³ÉµÄÆÁÕÏ£¬ÆäÖ÷ÒªÊÇһЩ½áµÞ×éÖ¯Éí·ÖµÄ»ìÏýÎ°üÀ¨½ºÔ­¡¢Õ³ÂÑ°×¼°ÂѰ׶àÌǵÈ ¡£×ªÒƵÄÖ×Áöϸ°û±ØÐë¾­¹ýÓëϸ°ûÍâ»ùÖʼäµÄһϵÁз´Ó¦£¬²Å»ª¹»ÇÖÏ®Àֳɣ¬ÐγÉתÒÆÁö ¡£Glinskii O V µÈ[31]ͨ¹ýÌåÍâÊÔÑé·¢Ã÷£¬MCP ÀÖ³ÉÒÖÖÆÁËÈËÈéÏÙ°©¼°¿ÚÇ»°©Ï¸°û´©¹ýÓÉÄÚƤϸ°û¹¹½¨µÄÈ˹¤»ùµ×ĤģÐÍ£¬²¢ÇÒÕâÖÖÒÖÖÆ×÷ÓóʼÁÁ¿ÒÀÀµÐÔ ¡£Sathisha U V µÈ[32]Ñо¿Ò²Ö¤ ʵÁË MCP ¾ßÓÐÒÖÖÆ°©Ï¸°ûÇÖÏ®Á¦µÄÄÜÁ¦ ¡£
    4.2.4 ÒÖÖÆÖ×Áöϸ°ûÔçÆÚתÒƵĿË¡ÊýËæ×ÅÖ×Áöϸ°ûÍ£ÁôÔÚÔ¶´¦Æ÷¹Ù²¢´©³öѪ¹Ü£¬ÆäÖеľø´ó´ó¶¼°©Ï¸°ûÃæÁÙ×ŵòÍö£¬Ö»Óв»µ½ 2%µÄ°©Ï¸°û´æ»î£¬ÐγÉ΢תÒÆ ¡£ÔçÆÚϸ°û¿Ë¡µÄ´æ»îÊÇÐγÉÓÐЧתÒƵÄÒªº¦ ¡£Nangia M P µÈ[33]Ñо¿ÈÏΪ£¬MCP ÄÜ ¹» Ã÷ ÏÔ Ó° Ïì Ìå Íâ Ѫ ¹Ü Èâ Áö ϸ °û µÄ ¿Ë ¡ ÐγÉ£¬²¢ÈÏΪÕâÒ»»úÖÆ¿ÉÄÜÓë½µµÍ Galectin-3 µÄ¿¹µòÍöÄÜÁ¦ÓйØ ¡£
    4.2.5 ÒÖÖÆÖ×ÁöѪ¹ÜÉú³É
    Ö×ÁöÉú³¤ÓëѪ¹ÜÐγÉÃÜÇÐÏà¹Ø£¬ÐÂÉúѪ¹ÜÉú³ÉÄÜÁ¦ÊÇÖ×ÁöÇÖÏ®ÐԵıê¼Ç ¡£MCP ÄÜÓ°ÏìÈËÄÚƤϸ°û¶ÔGalectin-3 µÄÇ÷»¯ÐÔ£¬½µµÍѪ¹ÜÉú³ÉÄÜÁ¦£¬²¢ÇÒÕâÖÖÒÖÖÆ×÷ÓóʼÁÁ¿ÒÀÀµÐÔ ¡£Nangia M P µÈ[33]ÌåÍâʵÑéÖ¤Ã÷ÓèÒÔŨ¶È 0.1%µÄMCP ¼´ÄÜÍêÈ«ÒÖÖÆѪ¹ÜÉú³É ¡£Liu H Y µÈ[34]ÔÚÌåÄÚʵÑéÖÐ֤ʵ¿Ú·þ MCP ÄÜ×è¶Ï¶àÖÖÖ×Áöϸ°ûµÄÉú³ÉºÍתÒÆ ¡£
    4.2.6 ϸ°û¶¾Ò©ÎïÔöÃô¼°»¯ÁÆÒ©Îï¶Ô¿¹ºóµÄÄæת
    Ö×Áöϸ°û¶Ô¿¹Ö×ÁöÒ©Îﱬ·¢ÄÍÒ©Êǵ¼ÖÂÖ×Áö»¯ÁÆʧ°ÜµÄÖ÷ÒªÒòËØ£¬Ò²ÊÇÀ§ÈÅÖ×ÁöÖÎÁƵÄÒªº¦ÐÔÄÑÌ⣬´ó¶¼»¼Õß»¯ÁÆÒ»¶Îʱ¼äºó±¬·¢²î±ðˮƽµÄÒ©Îï µÖ ¿¹ ÐÔ  ¡£ Chauhan D µÈ[ 35 ] ͨ ¹ý ʵ Ñé Ö¤ Ã÷ ÒÖ ÖÆ Galectin-3 ¿¹µòÍö¹¦Ð§£¬MCP ÄÜÏÖ×´Ôö¼ÓѪ¹ÜÈâÁöϸ°û¶Ô¶àÈá±ÈÐÇËùÓÕµ¼µòÍöµÄÃô¸ÐÐÔ£¬ÔöÇ¿¶à·¢ÐÔ¹ÇËèÁöϸ°û¶ÔµØÈûÃ×ËÉÓÕµ¼µòÍöµÄ·´Ó¦ÐÔ£¬Äæת¶à·¢ÐÔ¹ÇËèÁöϸ°û¶ÔÅðÌæ×ôÃ×µÄÄÍÒ©ÐÔ ¡£ÕâÖÖ×÷ÓÃÔÚÓ벬Àà¡¢æß¼îÀà¡¢ÅðÌæ×ôÃס¢°¢Ã¹ËØÀàµÈϸ°û¶¾Ò©Îï
    ÅäÏàÖúÓÃʱ¾ùÓÐÌåÏÖ ¡£
     
    5 Õ¹Íû
    µÍ·Ö×Ó¹û½ºµÄ¿¹Ö×ÁöÑо¿È¡µÃÁËÒ»¶¨µÄ½øÕ¹£¬µ«Æ俹Ö×Áö»úÖÆÉÐδÃ÷È·£¬Òò´ËÐèÒª´ÓÒÔÏ 4 ¸ö·½Ãæ½øÐÐÉîÈë̽Ë÷£º¹ØÓÚ¿¹°©¹û½ºµÄ·Ö×ÓÁ¿±ä¸ïºÍõ¥»¯¶È¶Ô¿¹Ö×ÁöЧ¹ûµÄÓ°ÏìÉÐδ¼û±¨µÀ£¬Òò´Ë¹¹Ð§¹ØϵµÄÑо¿¿ÉÒÔ¼ÓËÙ¿¹Ö×Áö¹û½ºÔÚÁÙ´²ÉϵÄÓ¦Óýø³Ì£»¿¹Ö×Áö¹û½ºµÄÑо¿Ö÷Òª¼¯ÖÐÓڽ᳦°©¡¢Ç°ÁÐÏÙ°©¡¢·Î°©¡¢¹¬¾±°©¡¢ÈéÏÙ°©¡¢·Î°©ºÍ¹ÇËè°©µÈÉÙÊý°©Ö¢£¬¶ø¹ØÓÚѪ°©¡¢ÁÜ°Í°©¡¢Î¸°©¡¢±ÇÑÊ°©µÈµÄÑо¿½ÏÉÙ£¬Òò´Ë£¬Èç¹ûÍØ¿í¿¹Ö×ÁöµÄ¹æÄ£Ñо¿ÓÐÖúÓÚÀ©´ó¹û½ºµÄÁÙ´²Ó¦ÓùæÄ££¬Ô츣¸ü¶à°©Ö¢»¼Õߣ»¹û½º¿¹Ö×Áö±¨µÀµÄÀ´Ô´ÓÐÆ»¹û¹û½º¡¢È˲ιû½º¡¢¸ÌéÙ¹û½ºµÈ£¬¶ø¹ØÓÚ²Ïɳ¹û½º¡¢ÏòÈÕ¿ûÅ̹û½º¡¢¶¹¸¯²ñ¹û½º¡¢ÄϹϹû½ºµÈµÄ¿¹Ö×ÁöЧ¹ûÉÐ䱨µÀ ¡£ÈôÄܹ»·¢Ã÷²î±ðÀ´Ô´µÄ¹û½º¿¹Ö×ÁöµÄÌØÒìÐÔÓÐËù²î±ð»òÕßÏàͬ£¬¿ÉÒÔÔö¼Ó¿¹Ö×Áö¹û½ºµÄÉú²úÁ¿£¬¼õÉÙ·ÅÆú×ÊÔ´µÄÀË·ÑÏÖÏó£»¹û½º¿ÉÒÔÔö½ø»¯ÁÆÒ©ÎﻯÁÆÀú³ÌÖеÄÃô¸ÐÐÔ£¬¶ø¹ØÓڵͷÖ×Ó¹û½ººÍ³£¼ûµÄ¿¹Ö×ÁöÒ©ÎïÊÇ·ñ±£´æЭͬ¡¢Þ׿¹¡¢Ïà¼Ó»òÕßÏà·´µÄ×÷Óñ¨µÀ½ÏÉÙ ¡£Òò´Ë£¬Èç¹ûÄܹ»Ì½Ë÷³ö¹û½ººÍ³£¼û»¯ÁÆÒ©ÎïµÄÏ໥×÷ÓùØϵ£¬½«ÓÐÀûÓÚÍØÕ¹µÍ·Ö×Ó¹û½ºÔÚ¿¹°©ÁÙ´²ÉϵÄÓ¦Óà ¡£
    ×ÛÉÏËùÊö£¬µÍ·Ö×Ó¹û½ºÔÚ¿¹Ö×ÁöÒ©ÎïµÄ¿ª·¢·½ÃæÓÐמ޴óµÄÓÅÊÆ£¬µ«½«Æä×÷ΪÁÙ´²Ö×ÁöÖÎÁƵÄÒ»ÏßÒ©Î»¹Ðè¶ÔÆ俹Ö×Áö»úÖƽøÐнøÒ»²½Ì½Ë÷£¬µÍ·Ö×Ó¹û½ºµÄ·Ö×ÓÁ¿¡¢õ¥»¯¶ÈºÍÀ´Ô´¹ØÓÚÆ俹Ö×ÁöЧ¹ûµÄÓ°ÏìÒÔ¼°ºÍ¿¹Ö×ÁöÒ©ÎïÏ໥×÷ÓùØϵÐèÒª½ø Ò»²½Ñо¿ ¡£
     
    ²Î¿¼ÎÄÏ×
    1 ÖÜËÉ.¹û½º×ÛºÏÂÛÊö.°²»Õʦרѧ±¨,1995(4)¡Ã76~80.
    2 ÕÅѧ½Ü,¹ù¿Æ,ËÕÑÞÁá.¹û½ºÑо¿Ð½øÕ¹.ÖйúʳƷѧ±¨,2010,10(1)¡Ã 167~174.
    3 ½¹ÔÆÅô,Ðìΰ,ÖìÐãÁé,µÈ.µÍõ¥¹û½ºµÄÖƱ¸¡¢Ó¦ÓúÍÑо¿½øÕ¹.ËÄ´¨¹¤ÒµÑ§ÔºÑ§±¨,2004(4)¡Ã57~58.
    4 Ellen G M, Nigel J B, Keith W W, et al. Pectin-an emerging new bioactive food polysaccharide. Trends Food Sci Tech, 2012, 24(2)¡Ã21~37.
    5 ÚùÏþæº,ÕÅ°®Õä,³Â½¨¹ú,µÈ.µÍ·Ö×Ó¸ÌéÙ¹û½º·Û¶ÔÌÇÄò²¡Ð¡ÊóѪÌÇѪ֬µÄµ÷Àí×÷ÓÃ.ÖйúÈ«¿Æҽѧ,2006,9(20)¡Ã1685~1686.
    6 ÕÅÎIJ©,Áõ³¤ÖÒ,¸ßÁÖ.¸ÄÐÔ¸ÌéÙ¹û½ºµÄÖƱ¸¡¢±íÕ÷¼°¿¹°©»îÐÔ.¸ßµÈѧУ»¯Ñ§Ñ§±¨,2010(5)¡Ã964~969.
    7 Íô·å,Áõº£Ó¥.µÍ·Ö×Ó¸ÌéÙ¹û½ºÔÚÖ×ÁöÖÎÁÆÖеÄÑо¿½øÕ¹.¹ã¶«Ò½Ñ§,2011,32(20)¡Ã2747~2749.
    8 Takayuki T, Kotaro S, Masshiro Y, et al. Inhibition of metastatic tumor formation in vivo by a bacteriophage display derived galectin-3 tar£­geting peptide. Clin Exp Metastas, 2013, 30(2)¡Ã119~132.
    9 ÕÅÎIJ©. MCP ¶àÌǵÄÖƱ¸¡¢ÆÊÎö¼°Æ俹Ö×Áö»îÐÔµÄÑо¿.Ìì½ò£ºÌì½ò´óѧ²©Ê¿Ñ§Î»ÂÛÎÄ,2006.
    10 ·¶ÓñÓ¨.È˲ιû½º¶Ôϸ°ûǨÒƵÄÓ°Ï켫Æä»úÀíÑо¿.³¤´º£º¶«±±Ê¦·¶´óѧ²©Ê¿Ñ§Î»ÂÛÎÄ,2010.
    11 ÐìºñΡ. µÍ·Ö×Ó¸ÌéÙ¹û½ºÉ±É˽᳦°©Ï¸°ûÀú³ÌÖÐÒªº¦µòÍöÂѰ׵ĻîÐÔ.¹ãÖÝ£º¹ãÖÝҽѧԺ˶ʿѧλÂÛÎÄ,2010.
    12 ÞÉÃçÃç. ¹û½º-ͪÂå·ÒÇ°Ò©µÄºÏ³É¡¢½á³¦°ÐÏòÐÔºÍҩЧѧÑо¿. Î÷°²£ºµÚËľüÒ½´óѧ˶ʿѧλÂÛÎÄ,2005.
    13 Guess B W, Scholz M C, Strum S B, et al. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Pro£­static Dis, 2003, 6(4)¡Ã301~304.
    14 Tin W W, Gaia C, Fabio S, et al. Pectin matrix as oral drug de£­livery vehicle for colon cancer treatment. AAPS Pharm Sci Tech, 2011,12(1)¡Ã201~214.
    15 Àî¼Ñ.È˲ιû½º-°¢Ã¹Ëظ´ºÏÎïµÄÖƱ¸ºÍ¿¹Ö×Áö»îÐÔ.³¤´º£º¶«±±Ê¦·¶´óѧ˶ʿѧλÂÛÎÄ,2007.
    16 Tazawa K, Ohkami H, Yamashita I, et al. Anticarcinogenic and/or antimetastatic action of apple pectin in experimental rat colon car£­cinogenesis and on hepatic metastasis rat model. Acs Symposium Series. J An Chem Soc, 1998,701¡Ã96~103.
    17 Victor J M, Nigel J B, Keith W, et al. The bioactivity of modified pectin fragments. J Lunn and J L Buttriss, 2013, 1(1)¡Ã21~37.
    18 Niture S K, Refai L. Plant pectin: A poteintial source for cancer suppression. Am J Pharmac and Toxico, 2013,8(1)¡Ã9~19.
    19 Dongowshi G, Lorenz A. Intestinal steroids in rats are influenced by the structural parameters of pectin. J Nutr Biochem, 2004, 15(4)¡Ã196~205.
    20 Ide T, Horii M, Yamamoto T, et al. Contrasting effects of water - soluble and water insoluble dietary fibers on bile acid conjugation and taurine metabolism in the rat. Lipids, 1990, 25(6)¡Ã335~340.
    21 Vladislav V, Glinsky, Raz A. Modified citrus pectin antimetastatic properties: one bullet, multiple targets. Carbohydrate Res, 2009, 344 (14)¡Ã1788~1791.
    22 Nangia M P, Nakahara S, Hogan V, et al. Galectin-3 in apoptosis, a novel therapeutic target. J Bioenerg Biomembr, 2007, 39(1)¡Ã79~84.
    23 Story J, Lord S. Bile salts: In vitro studies with fibre components.
      
    Progress on Anti-tumor Activity of Pectin
    Li Yinghua1 , Zhu Wei1, 2
    (1. The Fifth people's Hospital of shanghai, Fudan University, shanghai 200240, China;
    2. Industrial Technology Research Institute of Zhejiang University, Hangzhou 310029, China)
    ¡²World Science and Technology/Modernization of Traditional Chinese Medicine and Materia Medica¡³
    Abstract: In this article, we reviewed studies on anti-tumor activity of pectin in recent years through data retrieval. The tumor treatment effect with pectin and interaction among anti-tumor medications were summarized. The analysis was made on the effect of pectin and Galectin-3 in tumor in order to discuss the anti-tumor mechanism of pectin. Finally, the development trend of anti-tumor study of pectin was pointed out to provide references.
    Keywords: Pectin, anti-tumor, activity study, review
     
     
     
  • ÉÏһƪ£º¹û½ºÔÚ°©Ö¢ÖÎÁÆÖеÄÓ¦ÓÃ
    ÏÂһƪ£º¸ÄÐÔ¹û½ºµÄ¿¹Ö×Áö»úÖÆÑо¿½øÕ¹
  • ·µ»ØÐÂÎÅÁбí
 

    ÁªÏµ918²«ÌìÌÃ

  • µØµã£ºÕã½­Ê¡áéÖÝÊж«¸Û¾­¼Ã¿ª·¢Çø¶«¸Û4·2ºÅ
  • ÁªÏµµç»°£º0570£­8788056
  • ×ÉѯÈÈÏߣº400-7118-600
  • E-mail£ºzjgykp@163.com

Coptyright © 2018 zjgykp.com All Rights Reserved. °æȨËùÓÐ 918²«ÌìÌà  ¼¼ÊõÖ§³Ö£ºÕã½­Ö¥Â鿪ÃÅ  ÕãICP±¸19048970ºÅ-1|ºǫ́ÖÎÀí
ÍøÕ¾µØͼ
ÓÑÇéÁ´½Ó£º918²©ÌìÌÃÏÂÔØ  w88Óŵ¹ÙÍø  8868ÌåÓý  pgµç×Ó  Ã×ÀÖM6  ÈËÉú¾ÍÊDz«  yyÒ×ÓΠ ½ðÄê»á  ±ØÍþbetway  ÓÀÀÖF66  bwin±ØÓ®  K8¿­·¢¹ÙÍø  ÈËÉú¾ÍÊDz©  Ã×ÀÖM6¹ÙÍø  918²©ÌìÌÃ